Healthcare provider profile · identity verified

Arezo Farhangi, MD

Internal Medicine · DELRAY BEACH, FL · NPI 1225532195

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	447	180
Rosuvastatin Calcium	Rosuvastatin Calcium	386	143
Metformin Hcl	Metformin Hcl	275	105
Lisinopril	Lisinopril	255	106
Diclofenac Sodium	Diclofenac Sodium	247	163
Alendronate Sodium	Alendronate Sodium	206	61
Amlodipine Besylate	Amlodipine Besylate	195	94
Albuterol Sulfate Hfa	Albuterol Sulfate	190	95
Levothyroxine Sodium	Levothyroxine Sodium	178	77
Losartan Potassium	Losartan Potassium	163	68
Nifedipine Er	Nifedipine	159	66
Gabapentin	Gabapentin	153	59
Tamsulosin Hcl	Tamsulosin Hcl	151	71
Pantoprazole Sodium	Pantoprazole Sodium	142	87
Glipizide	Glipizide	138	53
Fluticasone Propionate	Fluticasone Propionate	128	95
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	126	47
Metoprolol Succinate	Metoprolol Succinate	115	46
Hydrochlorothiazide	Hydrochlorothiazide	114	50
Omeprazole	Omeprazole	102	54
Tizanidine Hcl	Tizanidine Hcl	102	77
Carvedilol	Carvedilol	99	43
Azithromycin	Azithromycin	97	82
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	94	35
Trazodone Hcl	Trazodone Hcl	92	42
Metoprolol Tartrate	Metoprolol Tartrate	91	36
Simvastatin	Simvastatin	91	34
Triamcinolone Acetonide	Triamcinolone Acetonide	90	66
Meloxicam	Meloxicam	89	60
Famotidine	Famotidine	88	57
Clopidogrel	Clopidogrel Bisulfate	81	32
Ozempic	Semaglutide	79	17
Methylprednisolone	Methylprednisolone	71	59
Prednisone	Prednisone	69	40
Ibuprofen	Ibuprofen	68	53
Sildenafil Citrate	Sildenafil Citrate	67	19
Zolpidem Tartrate	Zolpidem Tartrate	66	31
Allopurinol	Allopurinol	65	29
Ciprofloxacin Hcl	Ciprofloxacin Hcl	61	56
Sertraline Hcl	Sertraline Hcl	60	25
Finasteride	Finasteride	54	24
Pioglitazone Hcl	Pioglitazone Hcl	53	24
Warfarin Sodium	Warfarin Sodium	53	17
Duloxetine Hcl	Duloxetine Hcl	52	23
Valsartan	Valsartan	49	15
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	47	17
Eliquis	Apixaban	46	20
Citalopram Hbr	Citalopram Hydrobromide	44	18
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	42	32
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	41	suppressed
Jardiance	Empagliflozin	37	15
Furosemide	Furosemide	36	28
Escitalopram Oxalate	Escitalopram Oxalate	35	18
Latanoprost	Latanoprost	35	15
Mirtazapine	Mirtazapine	34	17
Clobetasol Propionate	Clobetasol Propionate	31	20
Metformin Hcl Er	Metformin Hcl	31	18
Naproxen	Naproxen	30	29
Xarelto	Rivaroxaban	28	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	27	27
Celecoxib	Celecoxib	26	11
Pravastatin Sodium	Pravastatin Sodium	26	12
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	25	suppressed
Chlorthalidone	Chlorthalidone	25	suppressed
Atenolol	Atenolol	24	11
Vitamin D2	Ergocalciferol (Vitamin D2)	24	18
Montelukast Sodium	Montelukast Sodium	23	14
Valacyclovir	Valacyclovir Hcl	23	16
Topiramate	Topiramate	22	11
Tramadol Hcl	Tramadol Hcl	22	14
Baclofen	Baclofen	21	17
Cephalexin	Cephalexin	21	20
Hydralazine Hcl	Hydralazine Hcl	21	suppressed
Ketoconazole	Ketoconazole	21	15
Potassium Chloride	Potassium Chloride	21	13
Dutasteride	Dutasteride	20	suppressed
Alprazolam	Alprazolam	19	16
Glimepiride	Glimepiride	19	11
Metronidazole	Metronidazole	19	16
Quetiapine Fumarate	Quetiapine Fumarate	19	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	19	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	11
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	18	suppressed
Bumetanide	Bumetanide	17	14
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	17	suppressed
Enalapril Maleate	Enalapril Maleate	17	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	17	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	16	suppressed
Amoxicillin	Amoxicillin	16	suppressed
Lorazepam	Lorazepam	16	suppressed
Mounjaro	Tirzepatide	16	suppressed
Ondansetron Odt	Ondansetron	16	16
Ezetimibe	Ezetimibe	14	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	14	suppressed
Ipratropium Bromide	Ipratropium Bromide	14	suppressed
Lactulose	Lactulose	14	13
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Temazepam	Temazepam	14	suppressed
Descovy	Emtricitabine/Tenofov Alafenam	13	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Nitroglycerin	Nitroglycerin	13	13
Propranolol Hcl	Propranolol Hcl	13	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Evotaz	Atazanavir Sulfate/Cobicistat	12	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Genvoya	Elviteg/Cob/Emtri/Tenof Alafen	12	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	12	suppressed
Levofloxacin	Levofloxacin	12	11
Memantine Hcl	Memantine Hcl	12	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	12	12
Pregabalin	Pregabalin	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	11	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Prolia	Denosumab	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error